BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. We examined the relationship between clinicopathological factors and clinical response to primary systemic chemotherapy (PSC) and outcome. METHODS: Twenty-five patients with IBC were examined. Twelve patients received an anthracycline-based regimen, and 13 patients received an anthracycline-and a taxane-containing regimen as PSC. The expression of hormone receptors and human epidermal growth factor receptor-2 (HER-2) was determined by immunohistochemistry. RESULTS: The overall clinical response rate was 64.0%. Clinical response to PSC was higher in patients with progesterone receptor (PgR)-positive (P = 0.01) and HER-2-negative (P = 0.03) tumors. Patients with fewer than ten involved axillary lymph nodes (P = 0.01 and P = 0.02, respectively) and with a clinical response to PSC (P = 0.02 and P = 0.01, respectively) showed better distant disease-free survival and overall survival. CONCLUSION: In patients with IBC, PgR-positive and HER-2-negative tumors are more sensitive to anthracycline-based PSC. Patients with extensive residual tumor (ten or more lymph-nodes involved, no response to PSC) after PSC had unfavorable prognoses.
BACKGROUND:Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer. We examined the relationship between clinicopathological factors and clinical response to primary systemic chemotherapy (PSC) and outcome. METHODS: Twenty-five patients with IBC were examined. Twelve patients received an anthracycline-based regimen, and 13 patients received an anthracycline-and a taxane-containing regimen as PSC. The expression of hormone receptors and human epidermal growth factor receptor-2 (HER-2) was determined by immunohistochemistry. RESULTS: The overall clinical response rate was 64.0%. Clinical response to PSC was higher in patients with progesterone receptor (PgR)-positive (P = 0.01) and HER-2-negative (P = 0.03) tumors. Patients with fewer than ten involved axillary lymph nodes (P = 0.01 and P = 0.02, respectively) and with a clinical response to PSC (P = 0.02 and P = 0.01, respectively) showed better distant disease-free survival and overall survival. CONCLUSION: In patients with IBC, PgR-positive and HER-2-negative tumors are more sensitive to anthracycline-based PSC. Patients with extensive residual tumor (ten or more lymph-nodes involved, no response to PSC) after PSC had unfavorable prognoses.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Corinne Veyret; Christelle Levy; Philippe Chollet; Yacine Merrouche; Henri Roche; Pierre Kerbrat; Pierre Fumoleau; Pierre Fargeot; Pierre Clavere; Bernard Chevallier Journal: Cancer Date: 2006-12-01 Impact factor: 6.860
Authors: Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Y Nieto; P J Cagnoni; S Nawaz; E J Shpall; R Yerushalmi; B Cook; P Russell; J McDermit; J Murphy; S I Bearman; R B Jones Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Sjoerd Rodenhuis; Marijke Bontenbal; Louk V A M Beex; John Wagstaff; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Harm van Tinteren; Hans L Peterse; Elisabeth M TenVergert; Elisabeth G E de Vries Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: George Somlo; Paul Frankel; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; Stephen Shibata; Peiguo Chu; Stephen Forman; Dean Lim; Przemyslaw Twardowski; Jeffrey Weitzel; Joseph Alvarnas; Neil Kogut; Jeffrey Schriber; Eleanor Fermin; Yun Yen; Lloyd Damon; James H Doroshow Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: G Somlo; J F Simpson; P Frankel; W Chow; L Leong; K Margolin; R Morgan; J Raschko; S Shibata; S Forman; N Kogut; M McNamara; A Molina; E Somlo; J H Doroshow Journal: Br J Cancer Date: 2002-07-29 Impact factor: 7.640